General-purpose antiviral drug candidate ‘CP-COV03’
Hyundai Bio recently acquired a global clinical trial agency (CRO) for emergency use approval and fast-track application to the U.S. Food and Drug Administration (FDA) for ‘CP-COV03’, a general-purpose antiviral drug candidate, as a treatment for COVID-19 and monkey pox. It announced on the 2nd that it has signed an advisory contract with IQVIA.
With this contract, Hyundai Bio plans to cooperate with CP-COV03 to quickly apply for emergency use approval to the FDA as a treatment for various viral diseases such as COVID-19 and monkey pox.
In addition, the company plans to establish ‘Hyundai Bioscience USA’ (tentative name) after Chuseok, a corporation that will apply for emergency use approval for CP-COV03 in the United States and conduct follow-up clinical related tasks.
A Hyundai Bio official said, “The help of an experienced global CRO is essential to apply for emergency use approval or fast track to the FDA, so we signed a contract with a world-class CRO this time. We plan to close it as soon as possible,” he said.
Reporter Jang Bom-i [email protected]
Copyrightⓒ ‘Honest knowledge for health’ Comedy.com (https://kormedi.com) / Unauthorized reproduction-redistribution prohibited
Source: 코메디닷컴 by kormedi.com.
*The article has been translated based on the content of 코메디닷컴 by kormedi.com. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!